"The new insulin product, which will be sold under the brand name Exubera by Pfizer, may be available as soon as this summer. But the picture isn't entirely rosy: Some doctors are worried that Exubera's risks to lungs have not been properly tested and that inhaled insulin causes minor declines in the amount of air the lungs can hold. The FDA recommended that asthmatics, smokers, and others avoid the product, and the long-term effects are still unknown.
The WSJ points out that it's been a good week for Pfizer: On Thursday, the FDA approved another of the company's drugs, Sutent, as a treatment for two kinds of cancer."
This was quoted without permission but should be adequately sourced to avoid violating copyright...
My MD thinks I'm still at least a decade from needing needles (injected insulin) and so I'll wait to see the long term results. I'm in no hurry to add the expense of yet another medication...
No comments:
Post a Comment